Clinical Trial: A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935928) titled 'A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)' on Oct. 06.

Brief Summary: This clinical trial uses a study drug (NP-101) alone in some parts of the study or with a recommended treatment for GEP-NEC called Nivo/Ipi (a combination of Nivolumab and Ipilimumab) in other parts of the study and tests it against Placebo (look alike capsules with no active drug) with Nivo/Ipi. The study is divided into three parts. Participants will participate in only one of 3 study...